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sUMMArY
Giving parenteral antibiotics to patients 
at home compared to in hospital presents 
unique challenges. 
The number of visits a health professional 
can make to a patient’s home per day and 
the stability of an antimicrobial drug in 
solution may restrict the choice of therapy. 
Novel administration methods and devices 
allowing bolus dosing or continuous infusions 
can be used to enable convenient and 
practical home treatment of many serious 
infections that have no oral therapy available. 
Identifying suitable patients and antimicrobials 
as well as appropriate monitoring is key for 
treatment to be successful. 
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and long distances between regional areas and 
metropolitan hospitals. 
patient selection
The selection of patients for admission to home 
programs is the key to ensuring that complications 
that require urgent intervention in the acute hospital 
environment are minimised. The following points  
need to be addressed before admission into a 
program:
1. It needs to be confirmed that parenteral antibiotics 
are truly required and that effective oral therapy 
cannot be given. Many conditions such as 
pneumonia and osteomyelitis can be effectively 
managed with oral antibiotics.
2. The patient needs to be well enough to be at 
home. Comorbidities such as unstable diabetes, 
relative hypoxaemia, severe pain, cognitive 
dysfunction and visual or auditory handicap are 
contraindications. 
3. The patient has to be willing to accept the 
program. Obligations of the patient and program 
of care should be discussed with the patient and 
carer.
4. The home environment must be suitable. There 
needs to be a clean, light area where intravenous 
line access can be performed. There also needs to 
be a refrigerator, telephone and a carer who is able 
to contact the program in an emergency.
5. Distance of the patient’s home from the treating 
centre needs to be taken into account in terms of 
frequency of visits.
6. A clear understanding of medical responsibility 
is essential. Many programs have their own 
medical staff and patient care responsibility is 
transferred to a doctor working in the program. 
Other programs are led by non-medical healthcare 
professionals and medical responsibility remains 
with the referring doctor. 
7. Home care should never be accepted when it is 
second best to inpatient management. Transfer 
to a home program when a patient threatens self-
discharge is strongly discouraged. Reasons for the 
patient’s desire to self-discharge against advice 
should be carefully sought and advice to remain 
in hospital should be communicated in a culturally 
appropriate and non-judgemental fashion. 
8. The presence of substance abuse such as 
alcoholism or illicit drugs is a contraindication.
introduction
Outpatient intravenous antimicrobial therapy has 
been practised in the USA since the 1970s and 
in Australia since the mid-1990s. A number of 
infections, such as acute cellulitis, lower respiratory 
tract infections and exacerbations of bronchiectasis, 
osteomyelitis and infective endocarditis, can now be 
treated safely at home. 
Many infections can be treated orally. However, 
because of increasing antibiotic resistance, many 
infections that were once treated with oral antibiotics 
have to be treated parenterally. 
Models of care
A number of programs for home-based therapy have 
been developed. They can be roughly divided into 
three categories:
 • healthcare professionals visit a patient’s home 
regularly to administer therapy
 • patient administers their own therapy at home 
after successful training
 • patient attends regular appointments at the 
hospital for treatment.
The first category, in which nurses and other health 
professionals visit patients to administer treatment, 
dominates in Australia and was first adopted in 
Victoria in 1994.1 Other programs do exist and the 
patient self-administration model is an attractive 
option in Australia given large geographical areas 
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9. Appropriate intravenous access is essential. In some 
circumstances, daily cannulation for once-daily 
intravenous therapy when the duration of therapy 
is likely to be only a few days may be the simplest 
option. Peripheral intravenous cannulae left in situ 
in the patient’s home are generally not a good 
option as they are less able to be well secured, have 
higher risks for infection or thrombophlebitis, and 
should be changed regularly. Patients requiring 
longer courses of therapy generally require a 
device that can remain in situ for a longer period 
of time. Peripherally inserted central cannulae 
have revolutionised intravenous antibiotic 
administration at home, and have in general low 
rates of complications. Increasingly, insertion 
of lines is performed in radiology departments 
where ultrasound guidance allows insertion into 
large veins in the upper arm, under full aseptic 
conditions. Other patients who may require 
frequent treatment courses for chronic conditions, 
such as cystic fibrosis, will have long-term tunnelled 
catheters such as Portacaths or Hickman lines.
indications for home intravenous 
therapy
Only a small number of bacterial infections need to be 
treated with intravenous antibiotics in the home. Many 
mild to moderate infections can be effectively treated 
with oral antibiotics. For example, mild to moderate 
pneumonia can generally be treated orally, and even 
more severe cases can be changed from intravenous 
medications to oral once the patient is stable.2 
Similarly, urosepsis such as pyelonephritis can often be 
treated with oral drugs initially if the patient is stable 
and not vomiting, or changed to oral therapy once 
stable and the microbiology results are available.2
Streptococcal cellulitis often does not respond to 
oral therapy, and in the absence of severe sepsis 
or comorbidity it is a suitable condition for initial 
intravenous antibiotics at home (Table 1). For example, 
once-daily intravenous cefazolin plus oral probenecid 
is effective for moderate to severe cellulitis.3
Patients who have been treated and stabilised in 
hospital and require prolonged courses of intravenous 
antibiotics are commonly treated at home. Examples 
of indications include infective endocarditis, 
osteomyelitis, infected prosthetic material, brain, lung 
and liver abscess, exacerbations of bronchiectasis 
or cystic fibrosis, and specific diseases such as 
melioidosis. Examples of intravenous antibiotic 
regimens given at home are listed in Table 1.
Antibiotic resistance
Unfortunately because of the increasing incidence of 
antibiotic resistance in hospitals and the community, 
many infections that once had oral antibiotic options 
now only have parenteral drugs available. The 
rise of community-acquired methicillin-resistant 
Staphylococcus aureus, multidrug resistant Escherichia 
coli urosepsis and multidrug resistant tuberculosis 
means that long courses of intravenous antibiotics are 
needed. This situation is becoming more frequent as 
the development of new antimicrobial drugs has all 
but come to a halt.
Antibiotic selection
When choosing an antibiotic, evidence-based 
guidelines should be followed.2 Only when the 
preferred therapy cannot be given in the home should 
an alternative broad spectrum drug be used. 
The resources of the home program may affect the 
choice of antibiotic. In practice, most services will 
only be able to visit a patient once a day, few can visit 
more often. The two key factors in assessing whether 
an antibiotic is appropriate for use in a home program 
are drug stability and administration intervals. Other 
factors, including toxicity and whether adequate 
monitoring is possible, are also important. 
Stability
Antibiotics must be sufficiently stable for the 
duration of the infusion or for extended periods if 
manufactured in advance. Stability is usually defined 
as greater than 90% of the original concentration 
remaining at the end of the infusion. Ampicillin and 
Table 1    examples of infections and treatments used in  
hospital in the home
Condition Treatment
Viridans streptococcal endocarditis Benzylpenicillin 10.8 g daily by continuous IV
MSSA blood stream infection Flucloxacillin 8 g daily via continuous IV
MSSA infective endocarditis Flucloxacillin 12 g daily via continuous IV
ESBL Escherichia coli UTI Ertapenem 1 g daily as an IV bolus
Streptococcal cellulitis Cefazolin 2 g IV daily with oral probenecid  
1 g daily
MRSA septic arthritis Vancomycin 1.5 g twice daily or 2–3 g daily via 
continuous IV (adjust for renal function and titrate  
to plasma concentrations)
Diabetic-foot osteomyelitis Ticarcillin/clavulanic acid 12.4 g daily via  
continuous IV
Bronchiectasis exacerbation Ceftazidime 6 g daily via continuous IV
Pneumococcal pneumonia Benzylpenicillin 7.2 g daily by continuous IV OR 
ceftriaxone 1 g daily IV
MSSA methicillin-sensitive Staphylococcus aureus
MRSA methicillin-resistant Staphylococcus aureus
ESBL extended spectrum beta-lactamase producing
UTI urinary tract infection
IV intravenous administration
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Table 2    drug administration intervals and pharmacological properties
Pharmacological property Goal Examples Administration method
Concentration-dependent killing Maximise the concentration above the minimum 
inhibitory concentration (Cmax:MIC)
Aminoglycosides Intermittent
Total exposure Maximise the total exposure of the body to the 
antibiotic (AUC:MIC)
Vancomycin
Fluoroquinolones
Intermittent/ continuous infusions
Time-dependent killing Maximise the time the concentration is above  
the minimum inhibitory concentration (T>MIC)
Beta-lactams
Lincosamides
Continuous infusions
Cmax maximum plasma drug concentration during a dosing interval
MIC minimum inhibitory concentration
AUC area under the plasma drug concentration-time curve
T time
maximise their effectiveness, but have a prolonged 
post-antibiotic effect. This allows time for the drug to 
be washed out, thereby minimising toxicity.  
Continuous infusions are appropriate if the antibiotic 
effectiveness is determined by the time (T) that the 
antibiotic remains above the minimum inhibitory 
concentration (MIC) and the drug is sufficiently stable. 
For example, beta-lactams (penicillins, cephalosporins 
and carbapenems) display this property so can be 
administered via continuous infusion. Unfortunately 
not all the beta-lactams are stable for 24 hours in 
solution. 
Twice-daily infusions of vancomycin or similar can be 
managed using programmable continuous ambulatory 
delivery pumps where the day’s supply of vancomycin 
is delivered as two infusions 12 hours apart. Given 
the practicalities of many home services however, 
continuous infusions are often used and evidence is 
emerging that this method is satisfactory although 
comparative trials are lacking. 
Monitoring
Monitoring patients enrolled in home programs is 
crucial to maximise efficacy and minimise toxicity. 
Therapeutic drug monitoring should be undertaken at 
least weekly for vancomycin and usually more often 
for aminoglycosides. There are very few indications 
such as multidrug resistant tuberculosis that warrant 
long-term aminoglycoside treatment and alternative 
antibiotics should always be used if appropriate.2 
Aminoglycoside toxicity is related to duration of 
therapy and patients being treated for longer than 
five days are at significantly increased risk of both 
renal and vestibular ototoxicity. Close monitoring 
including weekly audiometry is recommended. 
Therapeutic drug monitoring is available throughout 
Australia for other antibiotics including beta-lactams 
and teicoplanin, and may be useful in certain patients 
upon specialist advice. 
amoxicillin are commonly used in hospitals but are 
unsuitable for home programs given their low stability 
in aqueous solution.4
The stability of many antibiotics is temperature 
dependent and whilst they may be stable in a 
refrigerator for extended periods they can rapidly 
degrade at room and body temperature. This is an 
important consideration when giving continuous 
infusions. During an infusion, temperatures can reach 
more than 31˚ C.5,6 Benzylpenicillin, for example, 
is a useful antibiotic to treat many streptococcal 
and enterococcal infections. However unless the 
antibiotic is compounded using a buffer, it rapidly 
degrades with 1–5% remaining after 24 hours at body 
temperature.6,7
Meropenem, a carbapenem drug that is often required 
to treat multidrug resistant pathogens, is poorly 
stable in solution and is unsuitable for continuous 
infusions.8 A strategy where it is compounded and 
kept in the patient’s refrigerator, then given eight-
hourly rather than as a continuous infusion, helps 
overcome this problem. Continuous infusion with the 
bag of meropenem inside an ice pack has also been 
attempted. A large body of information exists on drug 
stability and specialty pharmacy services may be able 
to assist. 
Administration intervals
If the patient can only be visited once a day, 
prescribing of antibiotics is limited to either once-
daily bolus dosing or 24-hour infusions. The optimal 
method of administering an antibiotic will depend 
upon the pharmacological properties of the drug 
which can be separated into three categories – 
concentration-dependent killing, total exposure and 
time-dependent killing (Table 2).9 
Bolus administration is appropriate for antibiotics 
that exhibit concentration-dependent killing. 
Aminoglycosides require high peak concentrations to 
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Self-teSt 
queStionS
True or false? 
5. Meropenem can be 
given as a 24-hour 
continuous infusion.
6. Ampicillin is not 
suitable for hospital in 
the home because of 
stability problems.
Answers on page 211
potential harms
There are several risks for patients being treated in the 
home with intravenous antibiotics. Non-compliance 
with the non-antibiotic aspects of treatment such as 
bed rest, limb elevation and dressing changes can 
be a problem. Adverse events related to the venous 
access device are also of concern. A safety audit at 
our institution in 2009 revealed that approximately 
5% of patients experienced a complication with 
their peripherally inserted central catheter lines 
(for example clots, infections) – this equates to 
less than 1 per 1000 catheter days. Adverse drug 
reactions including anaphylaxis are also potential 
risks. Generalised skin eruptions from long courses 
of penicillins, cephalosporins and carbapenems may 
arise some weeks after starting therapy and may be 
heralded by a rising eosinophil count.
Conclusion
The treatment of infections with intravenous 
antibiotics in the home is an established treatment 
modality. Careful patient selection, safe intravenous 
access and appropriate training and monitoring 
means that many patients can be treated at home. 
Unfortunately, the rise of multidrug resistant infections 
means more patients will need prolonged courses of 
intravenous antibiotics.  
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224 pages 
You would be forgiven for thinking that a book about 
‘bugs’ is boring. From his basic training in infectious 
diseases at St Vincent’s Hospital in Melbourne, 
through life in the Northern Territory coordinating 
sexually-transmitted disease programs, to working 
as a staff specialist in Canberra, Frank Bowden’s 
colourful memoir is anything but boring. 
If you’ve ever wondered what happened to SARS 
(Severe Acute Respiratory Syndrome) or asked 
yourself why smallpox is the only disease to be 
eradicated by vaccination, this is the book for you. 
Swine flu, meningitis, MRSA (methicillin-resistant 
Staphylococcus aureus), necrotising fasciitis and 
donovanosis are but a few diseases you will 
encounter. Anecdotal stories bring this fascinating, 
terrifying and sometimes just plain gross topic to life. 
It is hard not to laugh out loud in parts, particularly 
when Professor Bowden describes the time he saw 
his first case of ‘saxophone penis’. However, it is not 
all fun and games. The chapter ‘Life during wartime’ 
is more sombre as he recounts life on the wards in the 
1980s during the HIV epidemic. Or the time he was 
called to the morgue to a schoolboy who went to bed 
feeling unwell only to be found dead in the morning 
from overwhelming meningococcal sepsis. 
The statistics on syphilis, gonorrhoea and chlamydia 
in Aboriginal women will shock you. Frank Bowden 
shares his sometimes controversial views on infection 
control and the ‘triumphs and failings’ of the health 
system in these communities. 
Despite it being a page turner, I did feel some points 
were laboured – the author dedicates a whole chapter 
to his personal experience of a needlestick incident 
during the initial years of HIV.  I also skimmed the 
chapter on hand hygiene in hospitals despite its 
interesting historical references to puerperal sepsis. 
This easy-to-read, witty account of life in a world of 
germs, complete with a glossary and index, has wide 
appeal. If you are a clinician, public health enthusiast 
or just wanting to know the facts behind the headlines, 
this book is as entertaining as it is informative and is 
perfect for a Sunday afternoon read. 
Fiona G Mackinnon PhD 
(Microbiology)
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